Evidence map›Paper›PMID 40530017›Full record

ArticleFrontiers in oncology2025

Title of report: second primary ovarian carcinomas after breast cancer diagnosis- an analysis of a single cancer centre in China.

Hong Liu, Min Luo, Chunrong Peng, Xinghan Cheng, Gupo Luo, Dengfeng Wang, Guonan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hong LiuGynecologic Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Min LuoDepartment of Oncology, The Sixth People's Hospital of Chengdu, Chengdu, China.
Chunrong PengGynecologic Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Xinghan ChengGynecologic Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Gupo LuoGynecologic Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Dengfeng WangGynecologic Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
Guonan ZhangGynecologic Oncology Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: We aimed to evaluate the clinicopathological characteristics and survival outcomes of patients with second primary ovarian carcinomas after a breast cancer diagnosis. Materials and methods: We reviewed the medical reports of 23 patients at Sichuan Cancer Hospital between May 2002 and October 2021. We analyzed demographic and clinicopathologic characteristics, the time interval between diagnoses, and survival time. Kaplan-Meier and Cox proportional hazards regression tests were used to determine survival outcomes. Results: The median age of patients at the time of diagnosis of breast cancer (BC) and ovarian cancer (OC) was 46 and 49 years, respectively. Among them were 6 cases of synchronous OC and 17 instances of metachronous OC. The average interval between diagnoses of the two cancers was 62.48 months. The median OS after the second primary OC diagnosis was 38 months. According to Kaplan-Meier's analysis, the advanced stage at presentation of BC (p=0.023) resulted in a significantly shorter interval between BC and OC diagnosis. On univariate Cox regression analysis, only BC Scarff-Bloom-Richardson (SBR) 3 Grade resulted in a considerably worse PFS (HR 0.187, p=0.048) and OS (HR 0.190, p=0.048), respectively. Conclusion: We should strengthen the follow-up management of breast cancer patients.The later the stage of breast cancer, the shorter the time interval of diagnosis of OC was. Early control of ovarian tumors and active comprehensive treatment for synchronous and metachronous breast and ovarian cancer can achieve good results.

Indexed as

breast cancerdouble primary malignancyinterval between diagnosesovarian cancersurvival outcome

Identifiers

PMID40530017
PMCPMC12170330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.